Medical Emergencies in Northern Ontario Remote First Nations: A cross-sectional descriptive study using Air Ambulance Transport Data to Understand Epidemiology

VanderBurgh et al. March 2020

STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies

	Item No	Recommendation
Title and abstract	1 $\sqrt{(a)}$ Indicate the study's designation	gn with a commonly used term in the title or the abstract
	(b) Provide in the abstract at	n informative and balanced summary of what was done
	• and what was found	
Introduction		
Background/rationale	$2\sqrt{2}$ Explain the scientific background and rationale for the investigation being reported	
Objectives	3 State specific objectives, including any prespecified hypotheses	
Methods	•	
Study design	4 Present key elements of stud	ly design early in the paper
Setting		ns, and relevant dates, including periods of recruitment,
	exposure, follow-up, and da	
Participants	6 (a) Give the eligibility criter	ria, and the sources and methods of selection of
Ĩ	participants	
Variables	7 Clearly define all outcomes,	exposures, predictors, potential confounders, and effect
	modifiers. Give diagnostic c	criteria, if applicable
Data sources/	8* For each variable of interest, give sources of data and details of methods of	
measurement	✓ assessment (measurement).	Describe comparability of assessment methods if there is
	more than one group	
Bias	$9 \sqrt{\text{Describe any efforts to addr}}$	ess potential sources of bias
Study size	10 Explain how the study size was arrived at	
Quantitative variables	11 Explain how quantitative va	riables were handled in the analyses. If applicable,
	describe which groupings w	ere chosen and why
Statistical methods	$12\sqrt{(a)}$ Describe all statistical m	ethods, including those used to control for confounding
	(b) Describe any methods us	sed to examine subgroups and interactions
	$\sqrt{(c)}$ Explain how missing dat	a were addressed
	N/A (<i>d</i>) If applicable, describe an	nalytical methods taking account of sampling strategy
	N/A (e) Describe any sensitivity	analyses
Results		
Participants	$13^* \checkmark$ (a) Report numbers of indiv	iduals at each stage of study—eg numbers potentially
	eligible, examined for eligib	ility, confirmed eligible, included in the study,
	completing follow-up, and a	nalysed
	N/A (b) Give reasons for non-par	rticipation at each stage
	(c) Consider use of a flow d	iagram
Descriptive data	14* (a) Give characteristics of st	udy participants (eg demographic, clinical, social) and
	information on exposures an	nd potential confounders
	(b) Indicate number of partic	cipants with missing data for each variable of interest
Outcome data	15^* V Report numbers of outcome	events or summary measures
Main results	V	es and, if applicable, confounder-adjusted estimates and
	their precision (eg, 95% con	fidence interval). Make clear which confounders were
	adjusted for and why they w	
		ries when continuous variables were categorized
		slating estimates of relative risk into absolute risk for a
	meaningful time period	
Other analyses	V	eg analyses of subgroups and interactions, and
	sensitivity analyses	

Discussion		
Key results	$18\sqrt{\text{Summarise key results with reference to study objectives}}$	
Limitations	19 Discuss limitations of the study, taking into account sources of potential bias or	
	¹⁹ Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	$20 \checkmark$ Give a cautious overall interpretation of results considering objectives, limitations,	
	multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21 Discuss the generalisability (external validity) of the study results	
Other information		
Funding	$22 \sqrt{\text{Give the source of funding and the role of the funders for the present study and, if}$	
	applicable, for the original study on which the present article is based	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.